Future development of JAK2‐selective or dual‐JAK inhibitors may help bridge the therapeutic gap for patients with concurrent RA and PV, offering more comprehensive control of both inflammatory and myeloproliferative activity. The gene discussed is JAK2; the disease is acquired polycythemia vera.